Nearly All Nursing Homes Fail Federal Rules on Anti-Psychotics
A year ago, the OIG, which is a branch of the U.S. Department of Health and Human Services, published a report saying that about half of anti-psychotic medications given to Medicare beneficiaries in nursing homes were not for medically accepted indications, and one in five were not given in accordance with federal safeguards to protect residents from unnecessary use.
The latest report takes the investigation one step further by looking at whether all four requirements in the process of determining appropriate use of those anti-psychotics in nursing homes were met.
The OIG recommends that the Centers for Medicare & Medicaid Services should do more to improve the process, specifically by modifying the survey "to target a small subsample of residents receiving anti-psychotic drugs focusing on the quality of care for these particularly vulnerable residents."
Also, CMS could require that nursing facilities document any efforts “to include the participation of residents, their families, or their legal representatives" in developing care plans.
- CVS Ramps Up Retail Clinics with Provider Affiliations
- 4 Tectonic Shifts Shaking Up Healthcare
- Medical Errors Third Leading Cause of Death, Senators Told
- As States Regulate Provider Competition, Common Threads Emerge
- Chronic Disease Care Costs Get Bipartisan Attention
- CareFirst Announces PCMH Program Results
- Mayo Tops U.S. News Best Hospitals Rankings
- Hospitals Seeking to Understand PPACA Impact Turn to Data
- Telemedicine Providers Welcome AMA Guidelines
- Roundtable: Life After a Healthcare Organization Acquisition